<DOC>
	<DOCNO>NCT01251406</DOCNO>
	<brief_summary>The mortality chronic heart failure patient remain high . Recombinant human Neuregulin-1 ( rhNRG-1 , also call Neucardin ) 61 amino acid peptide act directly damage heart muscle cell restore structure function . This study investigate safety efficacy rhNRG-1 treat stable chronic heart failure .</brief_summary>
	<brief_title>Efficacy Safety Human Neuregulin-1 Treat Stable Chronic Heart Failure</brief_title>
	<detailed_description>This randomize , parallel , placebo-controlled , double-blind , multi-center study ass safety efficacy rhNRG-1 also know Neucardin treatment stable chronic heart failure . A total 120 subject , chronic heart failure NYHA classification II III , stable regimen ACEI/angiotensin receptor blocker ( ARB ) , beta-blocker , and/or diuretic least 3 month prior receive study medication anticipate remain stable regimen treatment period enroll per specific inclusion exclusion criterion . Subjects hospitalize 10 day treatment period infuse subcutaneously rhNRG-1 placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age &gt; 18 year . Male female subject . Have chronic heart failure define NYHA classification II III . Be stable regimen ACEI/ARB and/or betablocker 3 month prior receive study medication expect remain stable HF medication regime throughout duration trial . Left ventricular ejection fraction ( LVEF ) &lt; 35 % determine screen 2D echocardiography . Is able understand provide inform consent . If subject dilate cardiomyopathy , ischemic heart disease correct valvular heart disease , surgery repair replace value , surgery must perform 3 month prior receive study medication surgical area function normally . Proper birth control must use least 3 week prior study ( woman ) , infusion period study drug ( men woman ) , 4weeks study drug administration ( men woman ) remain 11 month study followup ( woman ) . Women must negative pregnancy test screening . No great mild pericardial effusion &lt; 0.5 cm echocardiography ( roughly correspond &lt; 100 mL ) . Have implantable cardioverterdefibrillator ( ICD ) . The ICD implant least 3 month prior receive study medication . Patients undergo interrogation ICDs 1 7 day randomization drug previous thirty ( 30 ) day . This interrogation would include surveillance ventricular arrhythmias well assessment ICD discharge ( ) and/or antitachycardia pacing . Has chronic heart failure classify NYHA Class I IV . Has history malignancy positive test specify precancer screening . Have condition opinion investigator preclude participation study , e.g . serious comorbidity , know suspected substance abuse noncompliance . Has body weight &gt; 350lbs . Has cause hospitalization 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Stable</keyword>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Systolic</keyword>
</DOC>